SANOFI AVENTIS DEUTSCHLAND GMB

Company Introduction:

Sanofi is a global healthcare company headquartered in France, dedicated to human health. Sanofi Aventis Deutschland GmbH represents a key part of the global Sanofi group's operations in Germany. In India, Sanofi maintains a significant presence primarily through Sanofi India Limited (SIL), a publicly listed entity on Indian stock exchanges, and other group companies. Sanofi India Limited has a long and established history in the Indian pharmaceutical market, focusing on manufacturing, marketing, and distributing a broad portfolio of pharmaceutical products and vaccines. Its product range covers various therapeutic areas, including diabetes, cardiovascular diseases, central nervous system disorders, and consumer healthcare. The company is committed to delivering innovative healthcare solutions and improving patient lives in India.

Factory or Trader:

Based on its operations in India, primarily through Sanofi India Limited, Sanofi is both a manufacturer (factory) and a trader. Sanofi India Limited operates manufacturing facilities within India for the production of pharmaceutical formulations and active pharmaceutical ingredients. Additionally, it actively engages in the trading, sales, and distribution of its pharmaceutical products and vaccines across the Indian market.

The following products are part of Sanofi's global portfolio and are manufactured or sold in India. While SANOFI AVENTIS DEUTSCHLAND GMBH is the German entity of Sanofi, these products are generally marketed and distributed in India by Sanofi's local operations.

Lantus (Insulin Glargine)

Amaryl (Glimepiride)

Aprovel (Irbesartan)

Clexane (Enoxaparin)

Plavix (Clopidogrel)

Allegra (Fexofenadine)

Frisium (Clobazam)

Epilim (Sodium Valproate)

Hexaxim (DTP-IPV-Hib-HepB vaccine)

FluQuadri (Quadrivalent Influenza Vaccine)

Cerezyme (Imiglucerase)

Myozyme (Alglucosidase alfa)

Toujeo (Insulin Glargine U300)

Apidra (Insulin Glulisine)

Soliqua (Insulin Glargine and Lixisenatide)